影像学技术在银屑病共病筛查与评估中的应用进展

王永兴; 丁媛

doi:10.16766/j.cnki.issn.1674-4152.004098

影像学技术在银屑病共病筛查与评估中的应用进展

doi: 10.16766/j.cnki.issn.1674-4152.004098

王永兴¹,
丁媛^2, ,

1.
新疆医科大学研究生学院，新疆乌鲁木齐 830054
2.
新疆维吾尔自治区人民医院皮肤性病科，新疆皮肤性病临床医学研究中心，新疆皮肤病研究重点实验室，新疆乌鲁木齐 830054

基金项目:

国家自然科学基金项目 82360621

详细信息

通讯作者:
丁媛，E-mail：dydyuan@126.com

中图分类号: R758.63 R445
计量
- 文章访问数: 5
- HTML全文浏览量: 5
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2024-08-30
- 网络出版日期: 2025-10-25

Advances in the use of imaging techniques in the screening and evaluation of psoriasis co-morbidities

WANG Yongxing¹,
DING Yuan^{2
, ,}

1.
Graduate School of Xinjiang Medical University, Urumqi, Xinjiang 830054, China

摘要

摘要: 银屑病是一种常见的慢性炎症性疾病，全球发病率为1%~3%，我国的发病率约占0.47%，与之相关的共病包括银屑病关节炎、代谢综合征、非酒精性脂肪肝、葡萄膜炎、慢性肾病等。银屑病共病不仅影响银屑病患者的生活质量，同时还决定着患者的治疗措施；不同类型的银屑病共病患者使用生物制剂后，药物疗效产生了个体化的差异，因此早期筛查银屑病共病，对优化银屑病治疗有重要意义。近年来随着影像学技术快速发展，出现了许多新型的影像学检查，比如血管内超声(IVUS)、肌肉骨骼超声(MSUS)、荧光光学成像(FOI)和光学相干断层扫描血管成像(OCTA)等，这些影像学技术的出现，使得人们对人体信息的收集和处理更加敏感和特异，由于大部分影像检查具有非侵入性和简便性的特点，使影像学技术成为筛查与评估银屑病共病的有力工具。通过影像学技术评估关节、心血管、眼睛、肝脏等器官受累情况，可以提高银屑病共病早期诊断的准确性，为疾病活动及预后评估提供重要依据。因此在临床诊疗工作中，应该注重应用相关影像学检查措施，早期筛查、评估银屑病共病，从而能更好地辅助银屑病患者的诊治。在相关的前沿研究中，银屑病关节炎、心血管疾病和银屑病眼部损害方面的研究较多，本文就这些热点方面进行综述。
- 银屑病 /
- 共病 /
- 银屑病关节炎 /
- 影像学 /
- 筛查
Abstract: Psoriasis is a prevalent chronic inflammatory disease, with a global incidence rate ranging from 1 % to 3%, and an estimated prevalence of 0.47% in our country. Associated comorbidities include psoriatic arthritis, metabolic syndrome, non-alcoholic fatty liver disease, uveitis, and chronic kidney disease, among others. The utilization of biologics in patients diagnosed with various forms of psoriasis has resulted in individualized variations in drug efficacy. Psoriasis co-morbidities have been demonstrated to exert a detrimental effect on the quality of life of patients suffering from psoriasis patients, in addition to determining the treatment measures for said patients. The efficacy of drugs following the administration of biologics is subject to variation according to the specific co-morbidities associated with psoriasis, highlighting the importance of early screening for such co-morbidities in optimizing the treatment of psoriasis. The advent of advanced imaging technologies in recent years has given rise to a plethora of novel imaging modalities, including intravenous ultrasound (IVUS), musculoskeletal ultrasound (MSUS), fluorescence optical imaging (FOI), and optical coherence tomography angiography (OCTA), among others. The advent of these imaging technologies has rendered the collection and processing of information about the human body more sensitive and specific. Due to the non-invasive and simple nature of most imaging examinations, this technology has become a key component of screening and evaluation. The advent of imaging technology has rendered it a potent instrument in the screening and evaluation of psoriasis co-morbidities. The utilization of imaging technology for the assessment of joint involvement, cardiovascular complications, ocular manifestations, hepatic involvement, and other organ systems has been shown to enhance the precision of early psoriasis co-morbidities diagnoses. Moreover, it provides a substantial foundation for the assessment of disease activity and prognosis. Consequently, in clinical diagnosis and treatment, it is imperative to prioritize the implementation of pertinent imaging modalities for the screening and evaluation of psoriasis co-morbidities at an early stage, thereby facilitating more effective assistance in the diagnosis and treatment of psoriasis patients. Among the relevant cutting-edge studies, there are more studies on psoriatic arthritis, cardiovascular disease and psoriasis ocular damage, and this paper summarizes these hot aspects.
- Psoriasis /
- Complications /
- Cardiovascular diseases /
- Imaging /
- Screening

HTML全文

参考文献(43)

[1]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7): 573-625. Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China(2023 edition)[J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[2]	MEROLA J F, CHAKRAVARTY S D, CHOI O, et al. A clinical review of structural damage in psoriatic arthritis for dermatologists: from pathogenesis to ongoing controversies[J]. J Am Acad Dermatol, 2024, 90(2): 349-357. doi: 10.1016/j.jaad.2023.10.021
[3]	RUSSU E, GROPPA L, CHIŞLARI L, et al. Expressions and difficulty of clinical manifestations in the early diagnosis of psoriatic arthritis[J]. Mjhs, 2022, 28(2). DOI: 10.52645/mjhs.2022.2.05.
[4]	CHEN Z T, CHEN R F, LI X L, et al. The role of ultrasound in screening subclinical psoriatic arthritis in patients with moderate to severe psoriasis[J]. Eur Radiol, 2023, 33(6): 3943-3953. doi: 10.1007/s00330-023-09493-4
[5]	GROBELSKI J, WILSMANN-THEIS D, KARAKOSTAS P, et al. Prospective double-blind study on the value of musculoskeletal ultrasound by dermatologists as a screening instrument for psoriatic arthritis[J]. Rheumatology, 2023, 62(8): 2724-2731. doi: 10.1093/rheumatology/keac702
[6]	MAKSYMOWYCH W P, ØSTERGAARD M. Magnetic resonance imaging of axial and peripheral disease in psoriatic arthritis: a report from the 2020 GRAPPA annual meeting[J]. J Rheumatol, 2021. DOI: 10.3899/jrheum.201676.
[7]	PROFT F, LVDERS S, HUNTER T, et al. Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study[J]. Ann Rheum Dis, 2022, 81(11): 1534-1540. doi: 10.1136/ard-2022-222562
[8]	OTA M, NOBEYAMA Y, FUKUDA T, et al. Relationship between iodine-enhanced dual energy-computed tomographic findings and ultrasonographic findings for psoriatic arthritis[J]. J Dermatol, 2022, 49(3): 368-373. doi: 10.1111/1346-8138.16264
[9]	KOEHM M, OHRNDORF S, FOLDENAUER A C, et al. Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up[J]. RMD Open, 2022, 8(2): e002682. . DOI: 10.1136/rmdopen-2022-002682.
[10]	KÖHM M, OHRNDORF S, BARALIAKOS X, et al. POS1094 Correlation of fluorescence-optical imaging and physician tjc/sjc assessment and ultrasound in psoriasis patients without arthritis but musculoskeletal complaints within the last 6 months[J]. Ann Rheum Dis, 2022, 81(Suppl 1): 874.
[11]	BVTTNER J, GLIMM A M, KOKOLAKIS G, et al. Follow-Up comparison of fluorescence optical imaging with musculoskeletal ultrasound for early detection of psoriatic arthritis[J]. Front Med (Lausanne), 2022, 9: 845545. DOI: 10.3389/fmed.2022.845545.
[12]	SANTHOSH P, RIYAZ N, BAGDE P, et al. A cross-sectional study of nailfold capillary changes in psoriasis[J]. Indian Dermatol Online J, 2021, 12(6): 873-878. doi: 10.4103/idoj.IDOJ_793_20
[13]	PLATONOVA A, ZHUKOV A, VOLKOV K, et al. The prevalence incidence of psoriatic onychodystrophy and the significance of its symptoms for the diagnosis of psoriatic arthritis[J]. Vestn Dermatol Venerol, 2021, 97(6): 63-69. doi: 10.25208/vdv1262
[14]	ADAY A W, MATSUSHITA K. Epidemiology of peripheral artery disease and polyvascular disease[J]. Circ Res, 2021, 128(12): 1818-1832. doi: 10.1161/CIRCRESAHA.121.318535
[15]	CAI J, CUI L, WANG Y, et al. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis[J]. Front Pharmacol, 2021, 12: 774808. DOI: 10.3389/fphar.2021.774808.
[16]	李依明, 郑吟诗, 林光耀, 等. 颈动脉超声和能谱CT以及MR高分辨率管壁成像诊断颈动脉斑块稳定性的临床价值[J]. 中华全科医学, 2022, 20(10): 1737-1741, 1780. doi: 10.16766/j.cnki.issn.1674-4152.002692 LI Y M, ZHENG Y S, LIN G Y, et al. Clinical value of carotid ultrasound, energy spectral CT and MR high-resolution vessel wall imaging in judging the stability of carotid artery plaque[J]. Chinese Journal of General Practice, 2022, 20(10): 1737-1741, 1780. doi: 10.16766/j.cnki.issn.1674-4152.002692
[17]	NGUYEN H, VO P, PHAM N, et al. Carotid intima-media thickness in patients with psoriasis[J]. Open Dermatol J, 2021, 15(1): 45-51. doi: 10.2174/1874372202115010045
[18]	NGO V M, NGO H X, NGUYEN H T. Evaluating the femoral atherosclerotic plaque in psoriasis patients and controls: a case-control study[J]. J Psoriasis Psoriatic Arthritis, 2024: 24755303241288541. DOI: 10.1177/24755303241288541.
[19]	BIENSTOCK S, LIN F, BLANKSTEIN R, et al. Advances in coronary computed tomographic angiographic imaging of atherosclerosis for risk stratification and preventive care[J]. JACC Cardiovasc Imaging, 2023, 16(8): 1099-1115. doi: 10.1016/j.jcmg.2023.02.002
[20]	KAISER H, KVIST-HANSEN A, KRAKAUER M, et al. Association between vascular inflammation and inflammation in adipose tissue, spleen, and bone marrow in patients with psoriasis[J]. Life (Basel), 2021, 11(4): 305. DOI: 10.3390/life11040305.
[21]	YANG H C, POLY T N, ISLAM M M, et al. Increased risk of atrial fibrillation in patients with psoriasis: a meta-analysis of observational studies[J]. Indian J Dermatol Venereol Leprol, 2023, 89(1): 18-24.
[22]	ARYANIAN Z, JAFARIPOUR I, KOHNESHIN E, et al. Echocardiographic and electrocardiographic assessments in patients with psoriasis[J]. Caspian J Intern Med, 2021, 12(2): 162-166.
[23]	ROSENØ N A L, LØRUP E H, RICHARDSON C, et al. Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study[J]. Br J Dermatol, 2023, 188(3): 372-379. doi: 10.1093/bjd/ljac086
[24]	ZENG H, SHU Q, FANG J, et al. Linking psoriasis to atrial fibrillation: insights from "Association between psoriasis and atrial fibrillation: a systematic review and meta-analysis"[J]. Curr Probl Cardiol, 2025, 50(2): 102933. DOI: 10.1016/j.cpcardiol.2024.102933.
[25]	SUN Y, HOU J, LI X, et al. Prognostic value of left atrial longitudinal strain by cardiac MRI feature tracking in atrial fibrillation patients with mitral valve disease[J]. Clin Radiol, 2022, 77(8): e643-e651. doi: 10.1016/j.crad.2022.05.008
[26]	SIEWEKE J T, HAGEMUS J, BIBER S, et al. Echocardiographic parameters to predict atrial fibrillation in clinical routine-the EAHsy-AF risk score[J]. Front Cardiovasc Med, 2022, 9: 851474. DOI: 10.3389/fcvm.2022.851474.
[27]	杜笑青, 周梦, 石丽平, 等. 颈动脉内中膜厚度联合血清半乳凝集素-3和正五聚蛋白3对银屑病患者并发心血管疾病的诊断价值[J]. 实用临床医药杂志, 2024, 28(3): 84-89, 94. DU X Q, ZHOU M, SHI L P, et al. Diagnostic value of combining carotid intima-media thickness with serum galectin-3 and pentraxin 3 in patients with psoriasis complicated with cardiovascular disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 84-89, 94.
[28]	ARYANIAN Z, SHIRZADIAN A, HATAMI P, et al. Ocular manifestations of psoriasis: an inflammatory disease beyond the skin[J]. J Gen Fam Med, 2022, 24(1): 45-49.
[29]	AǦAÇKESEN A, GVNAYDIN N T, GÖKTAŞ E, et al. Evaluation of corneal topographic parameters in patients with psoriasis[J]. Photodiagnosis Photodyn Ther, 2023, 41: 103280. DOI: 10.1016/j.pdpdt.2023.103280.
[30]	KEMERIZ F, TUGRUL B, YASAR E. Evaluation of ocular psoriasis with meibography[J]. An Bras Dermatol, 2022, 97(1): 22-27. doi: 10.1016/j.abd.2021.05.008
[31]	SINGH A, KUMAR P, SINHA P, et al. An observational study on ocular manifestations in patients of psoriasis in a tertiary care hospital in western India[J]. Med J Armed Forces India, 2022, 78(Suppl 1): S186-S193.
[32]	TAHERI A R, ALLAHYARI E, ZEINALY M, et al. The study of dry eye and meibomian glands in psoriasis[J]. Eur J Ophthalmol, 2021: 11206721211007096. DOI: 10.1177/11206721211007096.
[33]	NETO I, ANTUNES A, MOYSÉS G. Ocular manifestations in psoriasis: a narrative bibliographic review/Manifestaçòes oculares na psoríase: uma revisão bibliográfica narrativa[J]. Braz J Dev, 2022, 8(5): 36557-36565. doi: 10.34117/bjdv8n5-254
[34]	ESMAT S, TOLBA D, ALORBANI A, et al. Corneal epithelial profile in psoriasis patients with and without dry eye disease[J]. Delta J Ophthalmol, 2022, 23(3): 141. doi: 10.4103/djo.djo_8_22
[35]	ERSAN I, KILIC S, IŞIK S. Evaluation of ocular surface epithelial and stromal thicknesses in psoriasis using anterior segment optical coherence tomography[J]. Int Ophthalmol, 2022, 42(10): 3037-3043. doi: 10.1007/s10792-022-02289-3
[36]	DAI Y X, TAI Y H, LEE D D, et al. Risk of retinal diseases in patients with psoriasis: a population-based cohort study in Taiwan[J]. J Dermatol, 2021, 48(10): 1550-1556. doi: 10.1111/1346-8138.16062
[37]	CASTELLINO N, LONGO A, FALLICO M, et al. Retinal vascular assessment in psoriasis: a multicenter study[J]. Front Neurosci, 2021, 15: 629401. DOI: 10.3389/fnins.2021.629401.
[38]	BELLINATO F, GISONDI P, MANTOVANI A, et al. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies[J]. J Endocrinol Invest, 2022, 45(7): 1277-1288. doi: 10.1007/s40618-022-01755-0
[39]	GU Q, CEN L, LAI J W, et al. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease[J]. Eur J Clin Invest, 2021, 51(2): e13446. DOI: 10.1111/eci.13446.
[40]	TORBATOR K, POO S, AL-RUBAYE T, et al. Whether screening for non-alcoholic fatty liver disease in patients with psoriasis is necessary: a pilot quality improvement project[J]. Cureus, 2022, 14(5): e24714. DOI: 10.7759/cureus.24714.
[41]	ZHANG X Z, GU H Q, XIE S, et al. Periodontitis in patients with psoriasis: a systematic review and meta-analysis[J]. Oral Dis, 2022, 28(1): 33-43. doi: 10.1111/odi.13617
[42]	COSTA A A, COTA L O M, ESTEVES LIMA R P, et al. The association between periodontitis and the impact of oral health on the quality of life of individuals with psoriasis and psoriatic arthritis[J]. PLoS One, 2024, 19(6): e0301158. DOI: 10.1371/journal.pone.0301158.
[43]	TOWNSEND D. Identification of venular capillary remodelling: a possible link to the development of periodontitis?[J]. J Periodontal Implant Sci, 2022, 52(1): 65-76. doi: 10.5051/jpis.2101160058